<DOC>
	<DOC>NCT00391846</DOC>
	<brief_summary>The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction</brief_summary>
	<brief_title>Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<mesh_term>Signs and Symptoms</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Captopril</mesh_term>
	<mesh_term>Trandolapril</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Natriuretic Peptide, Brain</mesh_term>
	<criteria>Female/male, over 18 years with previously verified HF with left ventricular systolic dysfunction. New York Heart Association(NYHA) class IIIV, NTproBNP males&gt;800 ng/L, females &gt;1000 ng/L Planned CV hospitalisation, stroke or acute myocardial infarction (MI) last 3 months, Mitral/aortic stenosis, Patients already receiving optimal HF treatment, Severe reduction of kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>NTproBNP</keyword>
</DOC>